VEGFR2 single-targeted contrast MBs could not effectively penetrate the leaky tumor vasculature to target the cancer cells, which are only used as blood-pool contrast agents for US molecular imaging and lack of tumor-targeting specificity. The gene discussed is KDR; the disease is neoplasm.